Challenger Provides First Quarter Performance

Challenger Limited

Challenger Limited (ASX: CGF) – To expand its distribution and product offering, reflecting the success of Challenger’s strategy, the company has reported strong growth in annuity sales. Brian Benari, Challenger’s Chief Executive Officer said, “With Challenger achieving its second highest quarterly result on record, annuity sales increased by 7% on the prior corresponding period.”

Reflecting both the benefit of a lower maturity rate compared to the prior corresponding period and higher Australian annuity sales, total Life book growth for the quarter was $425 million or 3.1%. With increasing retirement savings from the growing number of retirees, continued growth in annuity sales reflects strong demand for secure income. Also, from Challenger’s expanded distribution reach, annuity sales are benefiting.

By making its full range of annuities on the fast-growing specialist Netwealth platform available, Challenger also announced plans to further expand distribution. Demonstrating strong demand for advisers, this is the fifth retail platform to launch Challenger annuities, to be able to easily include annuities in their clients’ portfolios. [optin-monster-shortcode id=”swikrbu1d9j9aq0o4cko”]

Continue to benefit from higher average funds under management were the Funds management earnings, which was 14% higher than 12 months ago. Driven by both a lower annuity maturity rate and an increase in annuity sales, total Life net book growth was $425 million for the quarter. 3.1% of opening FY19 liabilities was the Life total book growth for the quarter.

Lower MS Primary (Japanese) and institutional sales, is offset by the strong growth in Australian annuity sales, total Life sales of $1,566 million were in line with the prior corresponding period. Up by $74 million or 7% on the pcp, were the total annuity sales of $1,171 million. Fixed term annuity sales, increased by 7% on the pcp, which include MS Primary. Australian fixed term annuity sales increased by $172 million or 25% on the pcp to $849 million.

Although sales were down 52% on the pcp, MS Primary sales increased 22% on the June 2018 quarter. Relative interest, reinsurance rate and foreign exchange rates are the factors Challenger’s level of MS Primary sales depends on. 6% higher than the pcp were the Lifetime annuity sales of $222 million benefiting from continued strong demand for CarePlus and confirmation of means testing treatment for lifetime income products.

Increasing by 5% on the pcp, were Net Life annuity flows for the quarter at $370 million. Of the opening FY19 Life annuity book, annuity book growth for the quarter represented 3.2%. On the pcp, sales of Other Life products were down $78 million, to $395 million.

At 30 September 2018, Life’s investment assets were at $18.3 billion, an increase of $0.3 billion for the quarter. As at October 17, 2018 the stock of CGF traded at a market price of $11.170.

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Checkout our Free Dividend Stocks Report

Specially made for income-hungry investors, Invest in growing Franked Dividends an opportunity that should not be missed.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report